Should You Get a Calcium Score Before a Weight-Loss Drug? Who Gains the Most Heart Protection

October 18, 2026

Say you’re carrying extra weight, you don’t have diabetes, and nobody has ever told you that you have heart disease. You’ve read that the weight-loss shots also protect the heart, and you want to know whether that is reason enough to start one.

My answer comes with a test attached. A ten-minute CT scan of the heart, the coronary calcium score, can tell us roughly how much heart protection one of these drugs would buy you. For some people the answer is a lot. For others it is close to nothing, at least for now. Two large analyses published in the past two years put numbers on that gap, and they are the reason I’d like to see the scan before the prescription in this situation.

What the heart evidence does and doesn’t cover

Semaglutide, sold for weight loss as Wegovy, is the drug with the heart data. In a trial of 17,604 adults aged 45 and up who were overweight or obese, did not have diabetes, and already had heart disease (a prior heart attack, a prior stroke, or blocked leg arteries), a weekly injection cut the combined rate of heart attack, stroke, and death from heart disease from 8.0 percent to 6.5 percent over a little more than three years. That is a 20 percent relative reduction, and in March 2024 the FDA added it to the label. Wegovy is approved to lower the risk of those events in adults with cardiovascular disease and either obesity or overweight. I walk through that evidence in my article on how GLP-1 drugs protect the heart.

Read the fine print on who was in the trial. Every one of those 17,604 people already had heart disease. People with extra weight and a clean record were not enrolled, so the trial can’t say directly what the drug does for them.

What it can say is how a benefit like this gets distributed. In the trial, 8 people in 100 on placebo had an event in about three years. On the drug it was 6.5. Put another way, roughly 67 people had to take it for three years to spare one of them a heart attack, stroke, or cardiovascular death. That arithmetic depends on how likely the event was to begin with. Lower the starting risk and the same 20 percent reduction spares fewer people, because there is less to prevent.

People with extra weight and no diagnosis are a mix. They range from people with clean arteries to people with advanced plaque they know nothing about. In the REACT study, silent plaque turned up in more than half of adults with no history of heart disease, and in more than nine in ten people in their 60s. Average the drug’s effect across that whole range and you get a modest number that describes almost nobody in it. Sort the range first and the picture changes.

A quick refresher on the calcium score

The coronary artery calcium score is a low-dose CT scan of the heart that counts the calcified plaque in the arteries that feed it. No needle, no dye, about ten minutes on the table, and most imaging centers will do it for roughly $75 to $200 if you pay cash. It returns a single number. Zero means no calcified plaque was found. The higher the number, the more plaque is there, and the higher the risk of a heart attack over the following years.

What separates it from a risk calculator is that it measures the disease. A calculator estimates your odds from your age, your cholesterol, your blood pressure, and whether you smoke. The scan looks at the arteries. Two people with identical numbers on paper can carry very different amounts of plaque, and the scan is what tells them apart.

A zero is reassuring for a few years, not for life. In the Multi-Ethnic Study of Atherosclerosis, a zero typically held for three to five years before calcium started to show, and less time than that in smokers, people with diabetes, and people with a strong family history of early heart disease. A zero also does not erase a high LDL, and I wrote a whole post on why I still treat the cholesterol when the scan is clean. And under 40 the score misses too much. Plaque has usually not calcified yet at that age, and in REACT about four in ten 30-somethings with coronary plaque on a CT angiogram had a calcium score of zero. Everything below assumes you are old enough for the test to mean something, which for most people is 40 and up.

Around 19 million chest CT scans are done in the United States every year for other reasons, a lung nodule, pneumonia, lung cancer screening, and the heart’s arteries are in the picture on every one of them. In late 2025 the American Heart Association said that calcium seen on those scans should be reported and acted on, and software that flags it automatically is already in use. A MESA study published this August scanned 2,472 people both ways on the same day and found the two readings agreed closely and predicted heart disease about equally well. If you have had a chest CT in the past few years, the answer to this question may already be in your chart.

The study that put the two together

A team led by Alexander Razavi at Emory took the Multi-Ethnic Study of Atherosclerosis, a long-running American heart study, and pulled out everyone who would have qualified for Wegovy on weight alone. That meant a body mass index of 27 or higher, no diabetes, and no known heart disease. They found 3,129 of them. Average age 61, just over half women, 62 percent non-White, average BMI about 32. Each had a calcium score at the start and then years of follow-up for heart attacks, strokes, heart failure, kidney disease, and death.

Half of them had a calcium score of zero. Eleven percent had a score of 300 or higher, which is a lot of plaque. Compared with the zeros, the people at 300 and above had 2.2 times the rate of major heart events (heart attack, stroke, or death from cardiovascular causes), 2.8 times the rate of heart failure, 1.6 times the rate of chronic kidney disease, and 35 percent higher mortality from any cause. Same weight range, same absence of a diagnosis, very different arteries.

The investigators then applied the risk reductions from the Wegovy trial and asked how many people in each calcium group you would have to treat for five years to prevent one event. To prevent one major heart event, the answer was 79 people in the high-calcium group and 653 in the zero group. Heart failure, 144 against 1,094. Death from any cause, 98 against 408. When they assumed everyone was already on a statin, which lowers the starting risk, the gap held at 72 against 599, and it was widest in people with a BMI of 35 or more. All of this appeared in January 2025 in JACC: Cardiovascular Imaging.

That is the same drug at the same dose with an eightfold difference in what it accomplishes, and the only thing separating the two groups was a scan that takes ten minutes.

It is the pattern you would expect if the drug works by protecting arteries that are already in trouble. A person with a score of 300 is building plaque, and every protective therapy we have is worth using. A person with a score of zero at the same weight has arteries that aren’t showing damage yet, and the case for a powerful drug purely on heart grounds is much weaker. They may still want it for weight or blood sugar, and that is a separate conversation worth having. For the heart alone, the benefit goes where the disease is.

A second, much larger dataset said the same thing

A modeling study from one cohort invites the question of whether it would hold up elsewhere. In February 2026 a second group answered with a registry of 38,058 people who had a calcium scan and met the Wegovy trial’s weight criteria, again without known heart disease. Compared with a zero score, a score of 400 or higher carried roughly twice the rate of a combined outcome of heart attack, heart failure, stroke, or death, and 1.6 times the death rate on its own.

They modeled 3.3 years of semaglutide, the length of the original trial, and got a number needed to treat of 151 at a score of zero and 34 at 400 and above. For heart failure the figures were 411 against 84, and for death from any cause 359 against 80. Those numbers are smaller than the Emory ones, in part because this outcome counted heart failure and deaths from any cause, and in part because the people differed. These were patients sent for a scan, not volunteers in a research cohort. The ratio is what carries over, a fourfold to eightfold difference in benefit driven entirely by what the scan showed.

The second group also ran the cost, which the first had not. Over a lifetime, at current drug prices, semaglutide cost about $626,000 for each year of healthy life it added in people with a zero score, and about $169,000 in people at 400 and above. Both figures are above the range US health economists usually treat as good value. What the scan did was move the drug from very poor value to merely expensive. That arithmetic will shift as prices move and coverage changes. Medicare, for one, now covers these drugs for weight loss through a $50-a-month bridge program for people who qualify.

More than the weight loss can explain

If the drug worked purely by taking weight off, you might expect the benefit to track the weight loss. It doesn’t. In the Wegovy trial the heart benefit showed up regardless of starting weight and regardless of how much weight people lost. A paper published last month by the trial investigators went further and tried to work out how much of the 20 percent reduction could be explained by the changes they measured over the first two years, in weight, waist size, blood pressure, cholesterol, blood sugar, inflammation, and kidney function. Put all of it together and it accounted for about a third. Weight loss by itself accounted for about a fifth, with a margin of uncertainty so wide that the statistics could not pin it down. Lead author Helen Colhoun’s summary was that no more than half of the reduction could be explained by those changes, and that semaglutide should be thought of as a cardiovascular drug in its own right.

Nobody knows yet what the rest of the benefit is. Inflammation inside the artery wall is the leading suspect. In a separate analysis of the same trial, hsCRP, a blood marker of inflammation, ended up about 38 percent lower on the drug than on placebo at two years, and it had started falling within the first month or two, while weight loss was still under 3 percent and even in people who lost little or nothing. The authors are careful to say that does not prove an effect separate from weight. For the question in this post the exact mechanism can wait. Whatever the drug is doing, it is doing it to a disease process, and a disease process has to be present for there to be something to protect. That is my reading of why the calcium score sorts people so cleanly. It measures whether the process is under way.

How I’d put this to work

If you are over 40, carrying extra weight, free of diabetes and known heart disease, and the heart is part of your reason for wanting one of these drugs, I want a calcium score before we decide. The scan is cheap and quick, and it changes the conversation in both directions.

With a high score, your arteries are already laying down plaque. That is the person I want on every protective therapy that applies, and the weight-loss drug is one of them, alongside a statin dosed to a real LDL target, blood pressure that comes back controlled on a home cuff, and the exercise and diet work that nothing replaces. The 2026 cholesterol guideline already treats a score of 300 or more much like known heart disease when it sets the LDL goal, which is under 55. I’d argue the heart benefit alone justifies the drug at that point, before weight ever comes up. Treat 79 people like this for five years and one of them is spared a heart attack, a stroke, or a cardiovascular death.

With a zero, your arteries aren’t showing damage, and the heart argument for the drug is weak for now. Treating 653 people for five years to spare one event is a trade I would never push on anyone who was reluctant. You may still want the drug, for weight, for blood sugar heading the wrong way, for your knees, for sleep apnea, and those are real reasons. I lay them out in my piece on GLP-1 medications for weight loss. The scan doesn’t veto that choice. It takes one argument off the table and leaves the others where they were. What a zero does not do is let you off the hook on cholesterol. If your LDL is high I will still want it treated, for the reasons in the zero-score post, and I’d want the scan repeated in three to seven years, which is what our 2026 cholesterol guideline advises when a zero is used to hold off on a statin. The same guideline says a zero should not be used to talk smokers, people with an inherited cholesterol disorder or an LDL over 190, or people with a strong family history of early heart disease out of treatment.

Scores in between, say 1 to 299, call for judgment, and I read them against age. A score of 80 at 50 worries me more than a score of 80 at 72, because it got there in far less time. For cholesterol, the guideline calls a moderate-dose statin reasonable at 1 to 99 and favors a statin at 100 and above. Any calcium at all tells me the process is under way, and in that situation I lean toward treating, with the drug if your weight qualifies you for it and with everything else regardless.

Under 40, I don’t use the scan for this decision, for the reasons above. Weight and metabolic health decide the drug question, and the LDL number decides the cholesterol question.

What this doesn’t settle

Both big analyses are models that took real event rates from real people sorted by calcium score and applied a risk reduction measured in a different population, people who already had heart disease. Nobody has run the trial that would close the loop, randomizing people with extra weight and a high calcium score to the drug or a placebo, and no trial of any of these drugs has shown that the relative benefit changes with the amount of plaque. The models assume it doesn’t, and the gap in absolute benefit comes from the gap in starting risk. No guideline tells doctors to order a calcium score before prescribing one of these drugs, and I don’t expect one to until a trial like that exists. What I’m describing is a reasoned use of two good pieces of evidence, and you should hear it described that way.

Something close to that trial is under way. Tirzepatide (Zepbound), the drug that beat semaglutide on weight loss in a head-to-head trial, is being tested in 15,374 adults with obesity and no diabetes for its effect on heart attacks, strokes, procedures to reopen blocked arteries, heart failure, and death, and the trial enrolled people with no established heart disease alongside people who have it. The trial is expected to finish in October 2027. It will tell us whether the heart benefit extends to people without a diagnosis, at least for tirzepatide. It will not tell us whether a calcium score should pick them, because it enrolled by risk factors on paper, which is the method REACT showed misses most of the plaque. Until it reads out, the heart-protection evidence in people without diabetes belongs to semaglutide, and both calcium-score analyses modeled semaglutide only. When I say “the drug” above, I mean Wegovy. For the real-world comparison of the two drugs so far, see my post on semaglutide versus tirzepatide for the heart.

Cost is the other open question. In the high-calcium group the cost model still put the drug above the usual US threshold for good value at current prices. That is a statement about prices, which are moving, and about insurance systems, which are slow, and it says nothing about the biology.

What to do with this

If you are weighing one of these drugs partly for your heart, you are over 40, and nobody has diagnosed you with heart disease or diabetes, ask your doctor for a coronary calcium score before you decide. Bring the number back to the conversation. A high score settles the heart question in favor of treating, with the drug and with everything else in the prevention toolkit, including blood pressure, LDL cholesterol, and the diet and movement work I describe in my piece on weight, exercise, and blood pressure. A zero tells you the heart argument can wait, the cholesterol argument cannot, and the other reasons for the drug stand or fall on their own.

If you already have heart disease, you don’t need the scan to justify the drug. The trial was done on you, and the label was written for you. If you have diabetes, the arithmetic is different again. These drugs have heart data of their own in diabetes, and in August the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk. The scan plays a smaller role there.

A few minutes in a CT scanner is what tells us which person is in the chair. Matching the intensity of treatment to the amount of disease is the core of preventive cardiology, and it is a conversation I’m glad to have, whether that is with me here in Encinitas or with your own cardiologist.

Frequently Asked Questions

What is a coronary artery calcium score?

A low-dose CT scan of the heart, about ten minutes with no needle or dye, that counts the calcified plaque in the arteries supplying the heart and reports it as one number. Zero means no calcified plaque was found and near-term heart attack risk is low. Higher numbers mean more plaque and higher risk. Most imaging centers charge roughly $75 to $200 if you pay cash.

Do GLP-1 drugs like semaglutide protect the heart?

In people who already have heart disease, yes. In a trial of 17,604 adults with overweight or obesity, no diabetes, and established cardiovascular disease, weekly semaglutide (Wegovy) cut heart attack, stroke, and cardiovascular death from 8.0 to 6.5 percent over about three years, a 20 percent relative reduction, and the FDA added that use to the label in March 2024. People with extra weight and no diagnosed heart disease were not in that trial, and for them the size of the benefit depends heavily on how much plaque they already carry.

How does a calcium score help decide about a weight-loss drug?

Two large analyses sorted people who met the Wegovy weight criteria, but had no diabetes or known heart disease, by calcium score and then applied the trial’s risk reduction. In the Multi-Ethnic Study of Atherosclerosis, 79 people with a score of 300 or higher would need five years of treatment to prevent one heart attack, stroke, or cardiovascular death, against 653 people with a score of zero. A separate registry of 38,058 people found a similar gradient and showed the drug was far better value at high scores. The scan concentrates the drug where the heart benefit is largest.

Does a calcium score of zero mean I shouldn’t take a GLP-1 drug?

No. It means the heart-protection argument is weak for now, so the decision rests on the other reasons, weight, blood sugar, joints, sleep apnea, which are valid on their own. A zero also does not excuse a high LDL. Cholesterol still gets treated, and the scan is usually repeated in three to seven years. A zero carries less reassurance if you smoke, have an inherited cholesterol disorder, or have a strong family history of early heart disease.

Does the heart benefit come from the weight loss?

Weight loss explains only part of it. In the trial the benefit appeared regardless of how much weight people lost. When the investigators measured how much of the 20 percent reduction could be explained by changes in weight, waist size, blood pressure, cholesterol, blood sugar, inflammation, and kidney function, the answer was about a third, and weight on its own accounted for about a fifth with wide uncertainty. What’s left is unexplained, and lower inflammation in the artery wall is the leading theory.

Is using a calcium score to guide these drugs an official recommendation?

No. No guideline requires or recommends a calcium score before prescribing a GLP-1 drug, and no randomized trial has tested the strategy. Two modeling studies built on real event data are the evidence so far. The 2026 cholesterol guideline does endorse the calcium score to guide statin decisions in men from 40 and women from 45 at borderline or intermediate risk, which is the same scan answering a neighboring question.

What about Zepbound (tirzepatide)?

Tirzepatide produces more weight loss than semaglutide, but its heart-outcomes trial in people with obesity and no diabetes, 15,374 adults including people without established heart disease, is expected to finish in October 2027. In August 2026 the FDA approved Mounjaro, the diabetes brand of tirzepatide, to lower heart risk in adults with type 2 diabetes at high cardiovascular risk, which does not extend to people without diabetes. Both calcium-score analyses modeled semaglutide only. Until the obesity trial reads out, the heart-protection evidence in people without diabetes belongs to semaglutide.

References

1. Razavi, Alexander C., Alexander M. Cao Zhang, Zeina A. Dardari, et al. “Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.” JACC: Cardiovascular Imaging 18, no. 4 (2025): 451-461.

2. Lincoff, A. Michael, Kirstine Brown-Frandsen, Helen M. Colhoun, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine 389, no. 24 (2023): 2221-2232.

3. Ponnana, Sai Rahul, Tong Zhang, Santosh Kumar Sirasapalli, et al. “Risk Stratification Using Coronary Artery Calcium and Potential Benefit of Semaglutide Therapy: A Cost-Effectiveness Modelling Study.” Diabetes, Obesity and Metabolism 28, no. 4 (2026): 3229-3237.

4. Colhoun, Helen M., A. Michael Lincoff, Donna Ryan, et al. “Semaglutide and Cardiovascular Risk Reduction: A Mediation Analysis of the SELECT Trial.” European Heart Journal (2026), published online September 23, 2026. doi:10.1093/eurheartj/ehag524.

5. Plutzky, Jorge, et al. SELECT trial analysis of high-sensitivity C-reactive protein with semaglutide. Circulation 154 (2026). doi:10.1161/CIRCULATIONAHA.125.074482.

6. U.S. Food and Drug Administration. “FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.” News release, March 8, 2024.

7. Bundgaard, Henning, Inés García-Lunar, Klaus F. Kofoed, et al. “Prevalence of Silent Atherosclerosis across Adult Life.” New England Journal of Medicine (2026). doi:10.1056/NEJMoa2609059.

8. Blumenthal, Roger S., Pamela B. Morris, Mario Gaudino, et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2026).

9. Foraker, Randi, Laurence Sperling, Lisa Bratzke, et al. “Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association.” Circulation 152, no. 19 (2025): e391-e401.

10. Verghese, Dhiran, et al. Paired same-day gated and nongated coronary artery calcium in the Multi-Ethnic Study of Atherosclerosis. Circulation 154 (2026): 302-312.

11. Eli Lilly and Company. FDA approval of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes, based on SURPASS-CVOT. Announcement, August 28, 2026.

12. Eli Lilly and Company. “A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO).” ClinicalTrials.gov identifier NCT05556512, record updated October 7, 2026.

13. Neale, Todd. “Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients.” TCTMD, July 22, 2024.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.